Brief: Mesoblast Says Allogeneic Cell Therapy Products Are Designated ‘U.S. Country Of Origin’ And Not Subject To U.S. Tariffs
04/04/2025 24:00
April 3 (Reuters) - Mesoblast Ltd MSB.AX: MESOBLAST ALLOGENEIC CELL THERAPY PRODUCTS ARE DESIGNATED ‘U.S. COUNTRY OF ORIGIN’ AND NOT SUBJECT TO U.S. TARIFFS Source text: ID:nGNX1QhS1R Further company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Mesoblast
See all newsBrief: Mesoblast William Burns To Retire From Board At 2026 AGM
Brief: Mesoblast Says Q1 Net Revenues Up 44%
Australia's Mesoblast hits one-month high on upbeat quarterly update
Australia's Mesoblast drops as Bell Potter cuts target price after key drug misses sales view
Brief: Mesoblast Says FDA Approves New Potency Assay For Commercial Ryoncil